Total Payments
$11,245
2024 Payments
$1,712
Companies
41
Transactions
702
Medicare Patients
4,248
Medicare Billing
$505,862
Payment Breakdown by Category
Food & Beverage$11,107 (98.8%)
Education$137.71 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,107 | 691 | 98.8% |
| Education | $137.71 | 11 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,970 | 187 | $0 (2024) |
| Janssen Biotech, Inc. | $1,378 | 87 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $902.57 | 59 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $809.44 | 62 | $0 (2024) |
| PFIZER INC. | $651.26 | 46 | $0 (2024) |
| Gilead Sciences, Inc. | $626.37 | 29 | $0 (2024) |
| Merck Sharp & Dohme LLC | $618.70 | 39 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $488.04 | 41 | $0 (2023) |
| Intercept Pharmaceuticals, Inc. | $486.61 | 29 | $0 (2024) |
| Braintree Laboratories, Inc. | $214.44 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,712 | 85 | ABBVIE INC. ($366.64) |
| 2023 | $1,834 | 105 | ABBVIE INC. ($413.30) |
| 2022 | $1,774 | 111 | ABBVIE INC. ($765.16) |
| 2021 | $1,342 | 97 | AbbVie Inc. ($297.08) |
| 2020 | $687.08 | 53 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($237.88) |
| 2019 | $1,585 | 106 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($267.87) |
| 2018 | $1,253 | 79 | AbbVie, Inc. ($404.96) |
| 2017 | $1,058 | 66 | AbbVie, Inc. ($280.40) |
All Payment Transactions
702 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $10.65 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/05/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: Rare Disease | ||||||
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | CapsoVision, Inc. | CapsoCam Plus (Device) | Food and Beverage | Cash or cash equivalent | $14.40 | General |
| Category: Gastroenterology | ||||||
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $29.38 | General |
| Category: Immunology | ||||||
| 10/29/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: VIROLOGY | ||||||
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/10/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/08/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INFLAM | ||||||
| 10/07/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Immunology | ||||||
| 09/30/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: LIVER DISEASE | ||||||
| 09/24/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: IMMUNOLOGY | ||||||
| 09/23/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Immunology | ||||||
| 09/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.24 | General |
| Category: Neuroscience | ||||||
| 09/12/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: VIROLOGY | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.66 | General |
| 09/03/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: INTERNAL MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 847 | 1,014 | $429,832 | $100,054 |
| 2022 | 18 | 1,018 | 1,276 | $534,966 | $123,201 |
| 2021 | 17 | 1,190 | 1,481 | $610,079 | $137,242 |
| 2020 | 15 | 1,193 | 1,672 | $610,259 | $145,365 |
Total Patients
4,248
Total Services
5,443
Medicare Billing
$505,862
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 91 | 91 | $94,588 | $17,249 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 117 | 164 | $23,124 | $13,804 | 59.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 44 | 126 | $19,434 | $7,677 | 39.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 125 | 125 | $90,076 | $7,250 | 8.0% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2023 | 13 | 13 | $23,015 | $7,019 | 30.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 59 | 59 | $49,469 | $6,363 | 12.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 56 | 56 | $12,432 | $6,181 | 49.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 54 | 62 | $15,126 | $6,118 | 40.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 32 | 32 | $23,726 | $5,641 | 23.8% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 41 | 43 | $19,810 | $4,868 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 81 | $7,985 | $4,779 | 59.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 17 | 17 | $13,013 | $2,859 | 22.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 21 | 21 | $16,310 | $2,841 | 17.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 30 | 36 | $3,240 | $2,134 | 65.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $4,628 | $1,956 | 42.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 20 | 22 | $2,860 | $1,780 | 62.2% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $10,650 | $1,440 | 13.5% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 19 | 23 | $345.00 | $96.37 | 27.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 110 | 112 | $115,144 | $20,864 | 18.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 63 | 220 | $33,933 | $12,046 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 96 | 116 | $16,356 | $10,387 | 63.5% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 15 | 16 | $28,326 | $9,395 | 33.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 107 | 147 | $14,406 | $8,682 | 60.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 48 | 48 | $37,245 | $8,509 | 22.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 138 | 145 | $104,705 | $8,467 | 8.1% |
About Dr. John Milliken, MD
Dr. John Milliken, MD is a Hepatology healthcare provider based in Traverse City, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013048057.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Milliken, MD has received a total of $11,245 in payments from pharmaceutical and medical device companies, with $1,712 received in 2024. These payments were reported across 702 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($11,107).
As a Medicare-enrolled provider, Milliken has provided services to 4,248 Medicare beneficiaries, totaling 5,443 services with total Medicare billing of $505,862. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Other Specialties Gastroenterology
- Location Traverse City, MI
- Active Since 03/09/2007
- Last Updated 12/23/2020
- Taxonomy Code 207RI0008X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013048057
Products in Payments
- STELARA (Biological) $1,042
- RINVOQ (Biological) $871.93
- XIFAXAN (Drug) $850.66
- Humira (Biological) $687.61
- XELJANZ (Drug) $556.85
- ENTYVIO (Biological) $514.34
- DIFICID (Drug) $513.31
- HUMIRA (Biological) $494.61
- OCALIVA (Drug) $472.19
- REMICADE (Biological) $320.77
- CLENPIQ (Drug) $291.10
- SKYRIZI (Biological) $286.98
- DUPIXENT (Biological) $190.89
- LINZESS (Drug) $173.05
- GATTEX (Drug) $172.48
- Cimzia (Drug) $167.76
- Trulance (Drug) $158.23
- Mavyret (Drug) $156.89
- AMJEVITA (Biological) $155.83
- SUTAB (Drug) $146.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.